Evaxion Biotech (EVAX) announces new positive preclinical data from its ongoing cytomegalovirus, CMV, vaccine program named EVX-V1. The data will be presented today at the 9th International Conference on Vaccines Research & Development, taking place in Boston, USA. The data demonstrates that the antigens identified with Evaxion’s AI-Immunology platform effectively trigger targeted immune responses, including induction of both CMV reactive B and T cells. To further enhance vaccine effectiveness, Evaxion has additionally designed a proprietary prefusion gB antigen, a well-established CMV vaccine component known to offer partial virus neutralization. New preclinical data confirms that Evaxion’s proprietary gB antigen successfully induced a specific immune response comparable to that of the conventional gB antigen.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EVAX:
- Evaxion Biotech Reports Q3 Progress and Financials
- Evaxion Biotech Shows Progress Amid Nasdaq Challenges
- Evaxion Biotech reports Q3 EPS (4c), consensus (31c)
- Evaxion Biotech to Announce Q3 Financial Results
- Evaxion Biotech’s AI Platform Shows Promising Trial Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
